Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Claudin-1 expression in cervical cancer.

Hoellen F, Waldmann A, Banz-Jansen C, Holtrich U, Karn T, Oberländer M, Habermann JK, Hörmann M, Köster F, Ribbat-Idel J, Thill M, Rody A, El-Balat A, Hanker L.

Mol Clin Oncol. 2017 Nov;7(5):880-884. doi: 10.3892/mco.2017.1391. Epub 2017 Aug 25.

2.

Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.

Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L.

JAMA Oncol. 2017 Dec 1;3(12):1707-1711. doi: 10.1001/jamaoncol.2017.2140.

3.

TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.

El-Balat A, Schmeil I, Karn T, Becker S, Sänger N, Holtrich U, Arsenic R.

Pathol Oncol Res. 2018 Apr;24(2):277-282. doi: 10.1007/s12253-017-0240-4. Epub 2017 May 3.

PMID:
28470574
4.

IMP3 Expression in Borderline Tumors of the Ovary.

El-Balat A, Sänger N, Karn T, Becker S, Holtrich U, Muallem Z, Arsenic R.

Anticancer Res. 2017 Feb;37(2):583-588.

PMID:
28179304
5.

Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.

Verma N, Müller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M, Mills GB, Nguyen LK, Shin S, Karn T, Holtrich U, Lev S.

Cancer Res. 2017 Jan 1;77(1):86-99. doi: 10.1158/0008-5472.CAN-16-1797. Epub 2016 Oct 28.

6.

Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters.

Hoellen F, Kostara A, Karn T, Holtrich U, El-Balat A, Otto M, Rody A, Hanker LC.

Mol Clin Oncol. 2016 Oct;5(4):422-428. Epub 2016 Aug 17.

7.

Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer.

Karn T, Rody A, Müller V, Schmidt M, Becker S, Holtrich U, Pusztai L.

Genom Data. 2014 Oct 23;2:354-6. doi: 10.1016/j.gdata.2014.09.014. eCollection 2014 Dec.

8.

The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers.

Karn T, Pusztai L, Rody A, Holtrich U, Becker S.

Curr Cancer Drug Targets. 2015;15(8):652-64. Review.

PMID:
26452382
9.

Fascin-1 expression as stratification marker in borderline epithelial tumours of the ovary.

El-Balat A, Arsenic R, Sänger N, Karn T, Becker S, Holtrich U, Engels K.

J Clin Pathol. 2016 Feb;69(2):142-8. doi: 10.1136/jclinpath-2015-203224. Epub 2015 Sep 11.

PMID:
26362828
10.

The prognostic impact of age in different molecular subtypes of breast cancer.

Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls EB, Lausen K, Hanker L, Holtrich U, Becker S, Karn T.

Breast Cancer Res Treat. 2015 Aug;152(3):667-73. doi: 10.1007/s10549-015-3491-3. Epub 2015 Jul 21.

PMID:
26195120
11.

Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.

Khan SS, Karn T, Symmans WF, Rody A, Müller V, Holtrich U, Becker S, Pusztai L, Hatzis C.

Breast Cancer Res Treat. 2015 Feb;149(3):789-97. doi: 10.1007/s10549-015-3277-7. Epub 2015 Feb 5.

PMID:
25651779
12.

Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers.

Sänger N, Engels K, Graf A, Ruckhäberle E, Effenberger KE, Fehm T, Holtrich U, Becker S, Karn T.

Geburtshilfe Frauenheilkd. 2014 Nov;74(11):1016-1022.

13.

Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer.

Sänger N, Ruckhäberle E, Györffy B, Engels K, Heinrich T, Fehm T, Graf A, Holtrich U, Becker S, Karn T.

Mol Oncol. 2015 Jan;9(1):58-67. doi: 10.1016/j.molonc.2014.07.016. Epub 2014 Jul 31.

14.

OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer.

Sänger N, Ruckhäberle E, Bianchini G, Heinrich T, Milde-Langosch K, Müller V, Rody A, Solomayer EF, Fehm T, Holtrich U, Becker S, Karn T.

Mol Oncol. 2014 Oct;8(7):1196-207. doi: 10.1016/j.molonc.2014.04.003. Epub 2014 Apr 15.

15.

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly C, Müller V, Schmidt S, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L.

Breast Cancer Res. 2013;15(5):R86.

16.

Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer.

Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Becker S, Holtrich U, Rody A, Darb-Esfahani S, Nekljudova V, von Minckwitz G.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1681-9. doi: 10.1007/s00432-013-1490-5. Epub 2013 Aug 18.

PMID:
23955546
17.

Acid ceramidase (AC)--a key enzyme of sphingolipid metabolism--correlates with better prognosis in epithelial ovarian cancer.

Hanker LC, Karn T, Holtrich U, Gätje R, Rody A, Heinrich T, Ruckhäberle E, Engels K.

Int J Gynecol Pathol. 2013 May;32(3):249-57. doi: 10.1097/PGP.0b013e3182673982.

PMID:
23518908
18.

Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer.

Hanker LC, Karn T, Holtrich U, Graeser M, Becker S, Reinhard J, Ruckhäberle E, Gevensleben H, Rody A.

Anticancer Res. 2013 Feb;33(2):371-7.

PMID:
23393326
19.

Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.

Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T.

Breast Cancer Res Treat. 2013 Jan;137(2):407-16. doi: 10.1007/s10549-012-2356-2. Epub 2012 Dec 16.

PMID:
23242614
20.

Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.

Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A.

PLoS One. 2011;6(12):e28403. doi: 10.1371/journal.pone.0028403. Epub 2011 Dec 29.

21.

A clinically relevant gene signature in triple negative and basal-like breast cancer.

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M.

Breast Cancer Res. 2011 Oct 6;13(5):R97. doi: 10.1186/bcr3035.

22.

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.

Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M.

Eur J Cancer. 2012 Jan;48(1):12-23. doi: 10.1016/j.ejca.2011.06.025. Epub 2011 Jul 7.

PMID:
21741824
23.

Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.

Karn T, Ruckhäberle E, Hanker L, Müller V, Schmidt M, Solbach C, Gätje R, Gehrmann M, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2011 Nov;130(2):409-20. doi: 10.1007/s10549-010-1333-x. Epub 2011 Jan 4.

PMID:
21203899
24.

SATB1 gene expression and breast cancer prognosis.

Hanker LC, Karn T, Mavrova-Risteska L, Ruckhäberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A, Wiegratz I.

Breast. 2011 Aug;20(4):309-13. doi: 10.1016/j.breast.2010.10.002. Epub 2010 Oct 25.

PMID:
20980149
25.

Breast Cancer Proteomics - Differences in Protein Expression between Estrogen Receptor-Positive and -Negative Tumors Identified by Tandem Mass Tag Technology.

Ruckhäberle E, Karn T, Hanker L, Schwarz J, Schulz-Knappe P, Kuhn K, Böhm G, Selzer S, Erhard N, Engels K, Holtrich U, Kaufmann M, Rody A.

Breast Care (Basel). 2010 Mar;5(1):7-10. Epub 2010 Feb 16.

26.

Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.

Ruckhäberle E, Karn T, Engels K, Turley H, Hanker L, Müller V, Schmidt M, Ahr A, Gaetje R, Holtrich U, Kaufmann M, Rody A.

Eur J Cancer. 2010 Feb;46(3):549-57. doi: 10.1016/j.ejca.2009.11.020. Epub 2009 Dec 18.

PMID:
20022486
27.

Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer.

Ruckhäberle E, Holtrich U, Engels K, Hanker L, Gätje R, Metzler D, Karn T, Kaufmann M, Rody A.

Climacteric. 2009 Dec;12(6):502-13. doi: 10.3109/13697130902939913.

PMID:
19905902
28.

Clinical relevance of the putative stem cell marker p63 in breast cancer.

Hanker L, Karn T, Ruckhaeberle E, Gaetje R, Solbach C, Schmidt M, Engels K, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2010 Aug;122(3):765-75. doi: 10.1007/s10549-009-0608-6. Epub 2009 Nov 7.

PMID:
19898932
29.

Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer.

Karn T, Metzler D, Ruckhäberle E, Hanker L, Gätje R, Solbach C, Ahr A, Schmidt M, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2010 Apr;120(3):567-79. doi: 10.1007/s10549-009-0416-z. Epub 2009 May 20.

PMID:
19455418
30.

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M.

Breast Cancer Res. 2009;11(2):R15. doi: 10.1186/bcr2234. Epub 2009 Mar 9.

31.

Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer.

Ruckhäberle E, Karn T, Rody A, Hanker L, Gätje R, Metzler D, Holtrich U, Kaufmann M.

J Cancer Res Clin Oncol. 2009 Aug;135(8):1005-13. doi: 10.1007/s00432-008-0536-6. Epub 2009 Jan 6.

PMID:
19125296
32.

Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers--results of a large scale microarray analysis.

Rody A, Karn T, Ruckhäberle E, Hanker L, Metzler D, Müller V, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M.

Eur J Cancer. 2009 Feb;45(3):405-13. doi: 10.1016/j.ejca.2008.10.016. Epub 2008 Dec 4.

PMID:
19054665
33.

Differential expression of claudins in human endometrium and endometriosis.

Gaetje R, Holtrich U, Engels K, Kissler S, Rody A, Karn T, Kaufmann M.

Gynecol Endocrinol. 2008 Aug;24(8):442-9. doi: 10.1080/09513590802242694.

PMID:
18850381
34.

Differentially expressed genes of reprogrammed human pluripotent stem cells in breast cancer.

Rody A, Karn T, Ruckhaeberle E, Hanker L, Gaetje R, Holtrich U, Kaufmann M.

Eur J Cancer. 2008 Sep;44(13):1789-92. doi: 10.1016/j.ejca.2008.06.037. Epub 2008 Aug 6.

PMID:
18691884
35.

Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.

Ruckhäberle E, Karn T, Hanker L, Gätje R, Metzler D, Holtrich U, Kaufmann M, Rody A.

J Cancer Res Clin Oncol. 2009 Jan;135(1):81-90. doi: 10.1007/s00432-008-0436-9. Epub 2008 Jun 17.

PMID:
18560890
36.

"Stem cell like" breast cancers-a model for the identification of new prognostic/predictive markers in endocrine responsive breast cancer exemplified by Plexin B1.

Rody A, Karn T, Holtrich U, Kaufmann M.

Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):11-5. doi: 10.1016/j.ejogrb.2008.02.015. Epub 2008 Apr 15.

PMID:
18417270
37.

Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.

Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M.

Breast Cancer Res Treat. 2009 Feb;113(3):457-66. doi: 10.1007/s10549-008-9964-x. Epub 2008 Mar 14.

PMID:
18340528
38.

Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.

Ruckhäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M.

Breast Cancer Res Treat. 2008 Nov;112(1):41-52. Epub 2007 Dec 4.

PMID:
18058224
39.

Expression of membrane-type 5 matrix metalloproteinase in human endometrium and endometriosis.

Gaetje R, Holtrich U, Engels K, Kourtis K, Cikrit E, Kissler S, Rody A, Karn T, Kaufmann M.

Gynecol Endocrinol. 2007 Oct;23(10):567-73.

PMID:
17952761
40.

Characterization of WNT7A expression in human endometrium and endometriotic lesions.

Gaetje R, Holtrich U, Karn T, Cikrit E, Engels K, Rody A, Kaufmann M.

Fertil Steril. 2007 Dec;88(6):1534-40. Epub 2007 Jun 27.

PMID:
17588571
41.

The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial.

Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhäberle E, Minckwitz GV, Loibl S, Holtrich U, Kaufmann M.

Breast. 2007 Jun;16(3):235-40. Epub 2007 Apr 20.

PMID:
17449250
42.

Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1.

Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, Loibl S, Diallo-Danebrock R, Ruckhäberle E, Metzler D, Ahr A, Solbach C, Karn T, Kaufmann M.

Clin Cancer Res. 2007 Feb 15;13(4):1115-22.

43.

Endometriosis may be generated by mimicking the ontogenetic development of the female genital tract.

Gaetje R, Holtrich U, Engels K, Kissler S, Rody A, Karn T, Kaufmann M.

Fertil Steril. 2007 Mar;87(3):651-6. Epub 2006 Nov 29.

PMID:
17140576
44.

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.

Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M.

Breast. 2007 Feb;16(1):86-93. Epub 2006 Sep 28.

PMID:
17010609
45.

[Identification of preeclampsia by cDNA-gene expression profiling in human placentas and serum -- a pilot study].

Ahr A, Holtrich U, Karn T, Reitter A, Rody A, Kaufmann M, Gätje R.

Zentralbl Gynakol. 2006 Jun;128(3):138-42. German.

PMID:
16758380
46.
47.

Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.

Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gätje R, Karn T, Kaufmann M.

Endocr Relat Cancer. 2005 Dec;12(4):903-16.

48.

Identification of high risk breast-cancer patients by gene expression profiling.

Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M.

Lancet. 2002 Jan 12;359(9301):131-2.

PMID:
11809257
49.

Molecular classification of breast cancer patients by gene expression profiling.

Ahr A, Holtrich U, Solbach C, Scharl A, Strebhardt K, Karn T, Kaufmann M.

J Pathol. 2001 Oct;195(3):312-20.

PMID:
11673828
50.

Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages.

Holtrich U, Wolf G, Yuan J, Bereiter-Hahn J, Karn T, Weiler M, Kauselmann G, Rehli M, Andreesen R, Kaufmann M, Kuhl D, Strebhardt K.

Oncogene. 2000 Oct 5;19(42):4832-9.

Supplemental Content

Loading ...
Support Center